ArticleOncogene2002
TMEFF2 is an androgen-regulated gene exhibiting antiproliferative effects in prostate cancer cells.
Article in Oncogene, 2002. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
37 citing papers in PubMed, 85 citations in OpenAlex.
- The path forward for T cell engagers in patients with prostate cancer.Journal for immunotherapy of cancer · 2026Review
- New frontiers in prostate cancer treatment from systemic therapy to targeted therapy.EMBO molecular medicine · 2025Review
- Article
- Identification of ferroptosis related genes and pathways in prostate cancer cells under erastin exposure.BMC urology · 2024Article
- Reconstructing Spatial Transcriptomics at the Single-cell Resolution with BayesDeep.bioRxiv : the preprint server for biology · 2023Article
- Reformation of the chondroitin sulfate glycocalyx enables progression of AR-independent prostate cancer.Nature communications · 2022Article
- Seed-mediated RNA interference of androgen signaling and survival networks induces cell death in prostate cancer cells.Molecular therapy. Nucleic acids · 2021Article
- TMEFF2 promoter hypermethylation is an unfavorable prognostic marker in gliomas.Cancer cell international · 2021Article
- Review
- The DNA methylation landscape of advanced prostate cancer.Nature genetics · 2020Article
- Genetic signature of prostate cancer mouse models resistant to optimized hK2 targeted α-particle therapy.Proceedings of the National Academy of Sciences of the United States of America · 2020Article
- Genome-wide effects of social status on DNA methylation in the brain of a cichlid fish, Astatotilapia burtoni.BMC genomics · 2019Article
- Expression of TMEFF2 in Human Pancreatic Cancer Tissue and the Effects of TMEFF2 Knockdown on Cell, Proliferation, and Apoptosis in Human Pancreatic Cell Lines.Medical science monitor : international medical journal of experimental and clinical research · 2019Article
- TMEFF2 inhibits pancreatic cancer cells proliferation, migration, and invasion by suppressing phosphorylation of the MAPK signaling pathway.OncoTargets and therapy · 2019Article
- TMEFF2 shedding is regulated by oxidative stress and mediated by ADAMs and transmembrane serine proteases implicated in prostate cancer.Cell biology international · 2018Article
- The effect of TMEFF2 methylation on the tumor stage and survival outcome of clear cell renal cell carcinoma.Cancer biomarkers : section A of Disease markers · 2017Article
- Acquired resistance to the second-generation androgen receptor antagonist enzalutamide in castration-resistant prostate cancer.Oncotarget · 2016Article
- Analysis of TMEFF2 allografts and transgenic mouse models reveals roles in prostate regeneration and cancer.The Prostate · 2016Article
- Specific and redundant activities of ETV1 and ETV4 in prostate cancer aggressiveness revealed by co-overexpression cellular contexts.Oncotarget · 2015Article
- Cell type specific gene expression analysis of prostate needle biopsies resolves tumor tissue heterogeneity.Oncotarget · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
Abstract
We have identified a gene that is highly expressed in the androgen-dependent prostate cancer cell line, LNCaP. Sequence analysis revealed that it was identical to a recently cloned gene designated TMEFF2, which encodes a transmembrane protein containing an epidermal growth factor (EGF)-like motif and two follistatin domains. This gene was highly expressed only in primary samples of normal prostate and prostate cancer as well as normal brain. Expression of the gene was controlled by androgen as shown by dihydrotestosterone markedly increasing TMEFF2 expression in LNCaP cells. Also, androgen-dependent human prostate cancer xenografts (CWR22) expressed high levels of TMEFF2 and these levels markedly decreased by day 10 after castration of the mice. Furthermore, a large number of androgen-dependent xenografts (CWR22, LuCaP-35, LAPC-4AD, LAPC-9AD) exhibited higher levels of TMEFF2 mRNA than androgen-independent xenografts (CWR22R, LAPC-3AI, LAPC-4AI, LAPC-9AI). Ectopic expression of TMEFF2 in DU145 and PC3 cells resulted in their prominent inhibition of growth. Taken together, the results demonstrate that TMEFF2 is a androgen-regulated gene, which can suppress growth of prostate cancer cells and our xenograft data show that escape of prostate cancer cells from androgen modulation causes them to decrease their expression of this gene, which may result in their more malignant behavior.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.